A
Alcista
Alcista · 25%XAIR
$0.58
Precio del escenario
$2.164
-0.016 (-0.72%)Al cierre
Loading chart…
- Máximo
- 2.249
- Apertura
- 2.160
- Precio medio ponderado por volumen
- 2.18
- Volumen
- 17.58K
- Capitalización
- 26.63M
- Mínimo
- 2.140
- Importe
- 38.40K
- EV/EBITDA, TTM
- -0.21
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Análisis de IA of Beyond Air Inc (XAIR)
ComprarBeyond Air Inc (XAIR) is a good buy right now due to its current price of $2.1643, which is significantly lower than the analyst price target of $10, indicating a potential upside of over 360%. Additionally, the company has received FDA Breakthrough Device Designation for its LungFit GO device, which could drive future revenue growth. However, the main risk is its high debt-to-equity ratio of 788.94%, indicating potential financial instability.
Métricas de valoración
El PER previsto actual de Beyond Air Inc (XAIR) es 0.00, frente a su media de 5 años de -1.87.
Escenarios de precio de Alphio AI para XAIR
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
6.509-18CNBCMusk Calls for AI Safety Regulation Amid Industry Debate
9.008-31NASDAQ.COMBeyond Air Receives FDA Breakthrough Device Designation for LungFit GO
9.008-31NewsfilterBeyond Air Receives FDA Breakthrough Device Designation for LungFit GO
8.508-25NASDAQ.COMBeyond Air Sells Majority Stake in NeuroNOS to UNIVO
2.008-14NASDAQ.COMBeyond Air (XAIR) Q1 2027 Earnings Call Transcript
Preguntas frecuentes sobre XAIR, respondidas por Alphio AI
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Beyond Air Inc (XAIR) is a good buy right now due to its current price of $2.1643, which is significantly lower than the analyst price target of $10, indicating a potential upside of over 360%. Additionally, the company has received FDA Breakthrough Device Designation for its LungFit GO device, which could drive future revenue growth. However, the main risk is its high debt-to-equity ratio of 788.94%, indicating potential financial instability.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.